Ghent University Academic Bibliography

Advanced

Similar efficacy and toxicity profile for Idarubicine and Mitoxantrone in induction and intensification treatment of children with acute myeloid leukemia (AML) or myelodysplasia (MDS): long-term results of the EORTC-CLG randomized phase III trial 58921

Barbara De Moerloose UGent, Stefan Suciu, Martine Munzer, Caroline Piette, Karima Yakouben, Genevieve Margueritte, Patrick Lutz, Anne Uyttebroeck, Pierre Rohrlich, Alina Ferster, et al. (2011) 53rd ASH annual meeting and exposition : abstracts, program and personal scheduler.
Please use this url to cite or link to this publication:
author
organization
year
type
conference
publication status
published
subject
in
53rd ASH annual meeting and exposition : abstracts, program and personal scheduler
article number
abstract 2615
publisher
American Society of Hematology (ASH)
conference name
53rd Annual meeting of the American Society of Hematology
conference location
San Diego, CA, USA
conference start
2011-12-10
conference end
2011-12-13
language
English
UGent publication?
yes
classification
C3
copyright statement
I have transferred the copyright for this publication to the publisher
id
2007966
handle
http://hdl.handle.net/1854/LU-2007966
alternative location
http://ash.confex.com/ash/2011/webprogram/Paper41962.html
date created
2012-01-30 15:43:39
date last changed
2016-12-21 15:40:52
@inproceedings{2007966,
  articleno    = {abstract 2615},
  author       = {De Moerloose, Barbara and Suciu, Stefan and Munzer, Martine and Piette, Caroline and Yakouben, Karima and Margueritte, Genevieve and Lutz, Patrick and Uyttebroeck, Anne and Rohrlich, Pierre and Ferster, Alina and Boutard, Patrick and Dresse, Marie-Fran\c{c}oise and Rialland, Xavier and Norton, Lucillia and Sirvent, Nicolas and Karrasch, Matthias and Benoit, Yves and Bertrand, Yves},
  booktitle    = {53rd ASH annual meeting and exposition : abstracts, program and personal scheduler},
  language     = {eng},
  location     = {San Diego, CA, USA},
  publisher    = {American Society of Hematology (ASH)},
  title        = {Similar efficacy and toxicity profile for Idarubicine and Mitoxantrone in induction and intensification treatment of children with acute myeloid leukemia (AML) or myelodysplasia (MDS): long-term results of the EORTC-CLG randomized phase III trial 58921},
  url          = {http://ash.confex.com/ash/2011/webprogram/Paper41962.html},
  year         = {2011},
}

Chicago
De Moerloose, Barbara, Stefan Suciu, Martine Munzer, Caroline Piette, Karima Yakouben, Genevieve Margueritte, Patrick Lutz, et al. 2011. “Similar Efficacy and Toxicity Profile for Idarubicine and Mitoxantrone in Induction and Intensification Treatment of Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS): Long-term Results of the EORTC-CLG Randomized Phase III Trial 58921.” In 53rd ASH Annual Meeting and Exposition : Abstracts, Program and Personal Scheduler. American Society of Hematology (ASH).
APA
De Moerloose, B., Suciu, S., Munzer, M., Piette, C., Yakouben, K., Margueritte, G., Lutz, P., et al. (2011). Similar efficacy and toxicity profile for Idarubicine and Mitoxantrone in induction and intensification treatment of children with acute myeloid leukemia (AML) or myelodysplasia (MDS): long-term results of the EORTC-CLG randomized phase III trial 58921. 53rd ASH annual meeting and exposition : abstracts, program and personal scheduler. Presented at the 53rd Annual meeting of the American Society of Hematology, American Society of Hematology (ASH).
Vancouver
1.
De Moerloose B, Suciu S, Munzer M, Piette C, Yakouben K, Margueritte G, et al. Similar efficacy and toxicity profile for Idarubicine and Mitoxantrone in induction and intensification treatment of children with acute myeloid leukemia (AML) or myelodysplasia (MDS): long-term results of the EORTC-CLG randomized phase III trial 58921. 53rd ASH annual meeting and exposition : abstracts, program and personal scheduler. American Society of Hematology (ASH); 2011.
MLA
De Moerloose, Barbara, Stefan Suciu, Martine Munzer, et al. “Similar Efficacy and Toxicity Profile for Idarubicine and Mitoxantrone in Induction and Intensification Treatment of Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS): Long-term Results of the EORTC-CLG Randomized Phase III Trial 58921.” 53rd ASH Annual Meeting and Exposition : Abstracts, Program and Personal Scheduler. American Society of Hematology (ASH), 2011. Print.